September 2021
First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
September 2021
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
November 2020
Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report
Seda Author(s) P.A. Dickinson
Date: November 2020
Published: Journal of Pharmaceutical Sciences